Results 11 to 20 of about 42,337 (292)

Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Côte d’Or (Burgundy, France)

Haematologica, 2011
Background Epidemiological data on myeloid malignancies are very rare in the literature due to a lack of registration by cancer registries until 2000.
Marc Maynadié, François Girodon, Ines Manivet-Janoray, Morgane Mounier, Francine Mugneret, François Bailly, Bernardine Favre, Denis Caillot, Tony Petrella, Michel Flesch, Paule-Marie Carli   +10 more
doaj   +1 more source

The myelodysplastic syndromes [PDF]

Clinical & Laboratory Haematology, 2008
Clinicomorphological features of myelodysplastic syndromes, Antonio Pagliuca and Ghulam J. Mufti FAB and MIC classification of myelodysplastic syndromes - points of controversy, John M. Bennett incidence and epidemiology of the myelodysplastic syndromes, R. A. Cartwright pathogenesis and evolution of refractory anaemia, A. Jacobs and D.
openaire   +3 more sources

Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes

Haematologica, 2009
The myelodysplastic syndromes are a group of clonal hematopoietic stem cell diseases characterized by cytopenia(s), dysplasia in one or more cell lineages and increased risk of evolution to acute myeloid leukemia (AML).
Arjan A. van de Loosdrecht, Canan Alhan, Marie Christine Béné, Matteo G. Della Porta, Angelika M. Dräger, Jean Feuillard, Patricia Font, Ulrich Germing, Detlef Haase, Christa H. Homburg, Robin Ireland, Joop H. Jansen, Wolfgang Kern, Luca Malcovati, Jeroen G. te Marvelde, Ghulam J. Mufti, Kiyoyuki Ogata, Alberto Orfao, Gert J. Ossenkoppele, Anna Porwit, Frank W. Preijers, Stephen J. Richards, Gerrit Jan Schuurhuis, Dolores Subirá, Peter Valent, Vincent H.J. van der Velden, Paresh Vyas, August H. Westra, Theo M. de Witte, Denise A. Wells, Michael R. Loken, Theresia M. Westers   +31 more
doaj   +1 more source

Infections in myelodysplastic syndromes

Haematologica, 2012
Myelodysplastic syndromes are associated with a risk of severe infections. While neutropenia is likely to be the main predisposing factor, several other immune defects have been reported, including impaired neutrophil function, B-, T- and NK-cell defects
Andréa Toma, Pierre Fenaux, François Dreyfus, Catherine Cordonnier   +3 more
doaj   +1 more source

Myelodysplastic Syndromes [PDF]

New England Journal of Medicine, 2009
Abstract Session 4 of the 2007 Workshop of the Society for Hematopathology/European Association for Haematopathology was devoted to myelodysplastic syndromes (MDSs). Submitted cases highlighted important issues and difficulties in relation to the diagnosis and classification of MDS.
Ayalew, Tefferi, James W, Vardiman
openaire   +4 more sources

Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes

Haematologica, 2017
Flow cytometric analysis is a recommended tool in the diagnosis of myelodysplastic syndromes. Current flow cytometric approaches evaluate the (im)mature myelo-/monocytic lineage with a median sensitivity and specificity of ~71% and ~93%, respectively. We
Eline M.P. Cremers, Theresia M. Westers, Canan Alhan, Claudia Cali, Heleen A. Visser-Wisselaar, Dana A. Chitu, Vincent H.J. van der Velden, Jeroen G. te Marvelde, Saskia K. Klein, Petra Muus, Edo Vellenga, Georgina E. de Greef, Marie-Cecile C.J.C. Legdeur, Pierre W. Wijermans, Marian J.P.L. Stevens-Kroef, Pedro da Silva-Coelho, Joop H. Jansen, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht   +18 more
doaj   +1 more source

Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

Haematologica, 2015
Although numerous recent publications have demonstrated interest in multiparameter flow cytometry in the investigation of myelodysplastic disorders, it is perceived by many laboratory hematologists as difficult and expensive, requiring a high level of ...
Valérie Bardet, Orianne Wagner-Ballon, Julien Guy, Céline Morvan, Camille Debord, Franck Trimoreau, Emmanuel Benayoun, Nicolas Chapuis, Nicolas Freynet, Cédric Rossi, Stéphanie Mathis, Marie-Pierre Gourin, Andréa Toma, Marie C. Béné, Jean Feuillard, Estelle Guérin   +15 more
doaj   +1 more source

Extramedullary Hematopoiesis in Myelodysplastic Syndromes: A Systematic Literature Review

Hemato, 2022
Extramedullary hematopoiesis is rarely seen in patients with myelodysplastic syndromes, and its clinical characterizations are not well-defined.
Chen Wang, Yiyun Shi
doaj   +1 more source

Marked upregulation of Survivin and Aurora-B kinase is associated with disease progression in the myelodysplastic syndromes

Haematologica, 2012
Background Myelodysplastic syndromes are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis. Survivin is a member of the inhibitor of apoptosis family and suppresses apoptosis.
Akira Yoshida, Kouichi Zokumasu, Yuji Wano, Takahiro Yamauchi, Shin Imamura, Kazutaka Takagi, Shinji Kishi, Yoshimasa Urasaki, Kaoru Tohyama, Takanori Ueda   +9 more
doaj   +1 more source

Myelodysplastic Syndrome with Transfusion Dependence Treated with Venetoclax

Case Reports in Hematology, 2020
Myelodysplastic syndromes are characterized by ineffective hematopoiesis in one or more lineages of the bone marrow. They are a group of heterogeneous clonal stem cell malignancies with a high risk to progress to acute myeloid leukemia.
Waqas Jehangir, Alexander Karabachev, Taimoor Jahangir, Elvira Umyarova   +3 more
doaj   +1 more source